Compared with wild-type CTNNB1, HCC patients with CTNNB1 mutation in TCGA-LIHC and cBioPortal databases were resistant to immunotherapies, suggesting that CTNNB1 might represent the biomarkers for predicting resistance to immune checkpoint inhibitors. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.